Publications
5813 Results
- Journal / Conference
- ASCO Annual Meeting (May 30 to June 3, 2025, Chicago, Il), oral, Abstract # 8003
- Year
- 2025
- Research Committee(s)
- Lung
- Study Number(s)
- S1914
SWOG/NRG S1914: A Randomized Phase III Trial of Induction/Consolidation Atezolizumab + SBRT versus SBRT Alone in High Risk, Early-Stage NSCLC
- Journal / Conference
- ASCO Annual Meeting (May 30 to June 3, 2025, Chicago, Il), poster; Abstract # TPS8113 Poster Bd # 234a
- Year
- 2025
- Research Committee(s)
- Lung
- Study Number(s)
- CTSU/A082304/S2402
Comparing impact of treatment before or after surgery in patients with stage II-IIIb resectable non-small cell lung cancer (NSCLC; Alliance A082304-SWOG S2402).
- Journal / Conference
- World Congress of Endourology (Sept 8-12, 2025, Phoenix, AZ)
- Year
- 2025
- Research Committee(s)
- Cancer Control
- Study Number(s)
- SWOG-9217
Urinary outcomes of International Prostate Symptom Score phenotypes following transurethral resection of the prostate: a secondary analysis of the Prostate Cancer Prevention Trial
- Journal / Conference
- ISOQOL Meeting (22-25 October 2025 Milwaukee, WI)
- Year
- 2025
- Research Committee(s)
- Palliative Care
- Study Number(s)
- S1316
Patient-reported outcomes (PROs) in the pragmatic comparative effectiveness trial of surgical versus non-surgical management for patients with malignant bowel obstruction (S1316)
- Journal / Conference
- Pharmacogenomics Research Network (PGRN) 2025 Annual Meeting (September 10-12, 2025, Mkssoula, MT)
- Year
- 2025
- Research Committee(s)
- Breast
- Study Number(s)
- S0221
EXTERNAL VALIDATION OF A POLYGENIC RISK SCORE FOR TAXANE-INDUCED PERIPHERAL NEUROPATHY: RESULTS FROM THE SWOG S0221 CLINICAL TRIAL
- Journal / Conference
- ASTRO Annual Meeting (9/27 to 10/1/2025, San Francisco, CA), oral, Abstract #: 258
- Year
- 2025
- Research Committee(s)
- Breast
- Study Number(s)
- S1706
Toxicity in a Randomized Trial Comparing Radiotherapy +/- Olaparib for Inflammatory Breast Cancer
- Journal / Conference
- ASCO GI Cancers Symposium (January 8 - 10, 2026, San Francisco, CA); J Clin Oncol 44, TPS790(2026); DOI: 10.1200/JCO.2026.44.2_suppl.TPS790
- Year
- 2025
- Research Committee(s)
- Palliative Care
- Study Number(s)
- S2408
S2408: A randomized phase III blinded trial of lanreotide for the prevention of postoperative pancreatic fistula
- Journal / Conference
- Journal of Clinical Oncology 2025 Mar 10;43(8):919-928. doi: 10.1200/JCO-24-01507. Epub 2024 Dec 2.
- Year
- 2025
- Research Committee(s)
- Breast
- PMID
- PMID39621968
- PMC
- PMC11885031
- Study Number(s)
- S1007, SWOG-8814
Development and Validation of the RSClinN+ Tool to Predict Prognosis and Chemotherapy Benefit for Hormone Receptor-Positive, Node-Positive Breast Cancer
- Journal / Conference
- Clinical Cancer Research Aug 14;31(16):3550-3561
- Year
- 2025
- Research Committee(s)
- Lung
- PMID
- PMID40465842
- Study Number(s)
- LUNGMAP
Elevated ctDNA Tumor Fraction Is Associated with Improved Mutation Detection but Worse Overall Survival in Advanced Non-Small Cell Lung Cancer: A Lung-MAP Study
- Journal / Conference
- Blood Neoplasia Jun 14;2(3):100129
- Year
- 2025
- Research Committee(s)
- Leukemia
- PMID
- PMID40792015
- PMC
- PMC12335950
- Study Number(s)
- S1203